The activation of caspases is a critical event for the execution phase of programmed cell death. Caspases are highly specific in their ability to activate or inhibit many crucial proteins in the cell via cleavage. In this study, we report the identification of several caspase-3-like cleavage sites in the cell-cycle checkpoint protein Rad9. We demonstrate that human Rad9 can be specifically cleaved in cells induced to enter apoptosis by both DNA damage and staurosporine treatment. Indeed, we show that human Rad9 can be effectively cleaved both in vitro and in vivo, which can be inhibited by either a pan-caspase inhibitor or a caspase-3-specific inhibitor. Additionally, no cleavage of Rad9 can be seen in the caspase-3-deficient cell line MCF-7. Site-directed mutagenesis of three of the most conserved cleavage sites dramatically abrogates cleavage of Rad9 by caspase-3 in vitro, and in intact cells after DNA damage. Expression of the cleavage-resistant mutant Rad9 DDD/AAA appears to protect the cell from DNA damage-induced apoptosis. Immunofluorescence studies of Rad9 localization before and after induction of apoptosis show a translocation of Rad9 from the nucleus to the cytosol, concomitant to the appearance of apoptotic morphology. Furthermore, analysis of a truncated Rad9 mutant that corresponds to a putative Nterminal cleavage fragment shows that the N-terminal portion of Rad9 localizes in the cytosol, binds to Bcl-XL, and induces apoptosis. These results support a dual role for cleavage of Rad9: (1) the liberation and translocation of the BH3 domain-containing N-terminus of Rad9 to the cytosol, as a means of promoting apoptosis via antagonism of Bcl-XL, and (2) the disruption of the Rad9-Rad1-Hus1 DNA damage checkpoint complex.
Introduction
Apoptosis is an evolutionarily conserved process of cell suicide that is both morphologically and biochemically distinct from necrosis. Grossly, apoptotic cells exhibit a variety of identifiable characteristics such as membrane blebbing, chromatin condensation, and typically, fragmentation into membrane-enclosed vesicles (Earnshaw et al., 1999) . Biochemical changes include the externalization of phosphatidylserine, degradation of chromosomal DNA into high-molecular-weight oligonucleosomal fragments, and cleavage of specific polypeptides such as PARP, ICAD, and antiapoptotic proteins such as Bcl-2 and Bcl-XL.
Many stimuli that trigger apoptosis without ligating death receptors cause mitochondria to release the electron transport protein cytochrome c to the cytosol (Green and Reed, 1998) . Apaf-1 binds the released cytochrome c, and then undergoes a nucleotide-dependent conformational change that allows the binding of procaspase-9. As a consequence of this binding, procaspase-9 is cleaved to active caspase-9, which in turn leads to activation of the downstream effector caspase-3, -6, and -7. These effector caspases then directly cause the morphological changes associated with apoptosis by specifically cleaving 'death substrates' (Earnshaw et al., 1999) . Caspases cleave a limited number of cellular proteins, and the process is one of limited proteolysis (Salvesen and Dixit, 1997) . Owing to their substrate specificity, caspase-mediated cleavage can result in activation or inactivation of their protein substrates, but never degradation (Salvesen and Dixit, 1997) .
The Bcl-2 family is comprised of well over a dozen proteins, which have been classified into three functional groups (Wang and Reed, 1998) . Members of the first group such as Bcl-2 and Bcl-XL contain four conserved Bcl-2 homology (BH) domains (BH1-BH4), and possess antiapoptotic activity. In contrast, group II consists of proapoptotic Bcl-2 family members including Bax and Bak, which have a similar overall structure to group I proteins but lack the N-terminal BH4 domain. Group III consists of a large and diverse collection of proapoptotic proteins whose only common feature is the presence of the BH3 domain. The Bcl-2 family of proteins appears to control the 'decision' step of apoptosis, determining whether certain caspases will or will not become activated (Reed, 1998) . Antiapoptotic members of the Bcl-2 family tend to prevent activation of these terminal effector proteases by blocking the release of apoptogenic molecules such as cytochrome c from the mitochondria. Conversely, proapoptotic Bcl-2 family members facilitate caspase activation by promoting the release of cytochrome c from the mitochondria.
In response to DNA damage, which can arise spontaneously from replication errors or from exogenous agents, a rapid-surveillance signaling cascade called the DNA damage checkpoint is initiated (Caspari and Carr, 2002) . Activation of this cascade results in cellcycle arrest, which provides time for the damage to be repaired. Deregulation of this checkpoint can lead to genomic instability that is associated with genetic diseases such as cancer (Hartwell and Kastan, 1994) . The Rad family of checkpoint proteins have emerged not only as critical mediators of this damage response pathway but also as putative apical sensors in the DNA damage checkpoint. Indeed, three members of the Rad family Rad9, Rad1, and Hus1 have been shown to interact with each other in a manner similar to the proliferating cell nuclear antigen (PCNA) (O'Connell et al., 2000) . Furthermore, a fourth Rad family member, Rad17, bears structural similarity to replication factor C (RFC), the clamp loader which places PCNA onto DNA (Tsurimoto, 1999; Venclovas and Thelen, 2000) . It is believed that, in times of damage, these four proteins form a putative DNA damage sensor, which encircles damaged DNA and relays the damage signal to downstream effectors (Zhou and Elledge, 2000; Wahl and Carr, 2001 ). In addition, it was shown that Rad9 could interact with Bcl-2 and Bcl-XL via a conserved BH3 domain located in the N-terminus of the Rad9 protein to antagonize the protective function of these proteins, promoting apoptosis (Komatsu et al., 2000a, b; Yoshida et al., 2002) . It has also been demonstrated that Rad9 can be phosphorylated on Tyr-28 within the BH3 domain by c-Abl, and that this phosphorylation promotes the interaction of Rad9 with Bcl-XL (Yoshida et al., 2002) .
In this study, we demonstrate that Rad9 possess several potential caspase-3 cleavage sites and can be cleaved by caspase-3 both in vitro and in vivo. After exposure to DNA-damaging agents or staurosporine (STS), Rad9 undergoes proteolysis and cytosolic translocation, which can be blocked by caspase inhibitors. Mutating the caspase-3 cleavage sites in Rad9 blocks cleavage in vivo, and also appears to protect the cell from death induced by DNA-damaging agents. Furthermore, Rad9DC, a mutant Rad9 that lacks the Cterminus and thus mimics a potential N-terminal cleavage fragment of Rad9, retains the ability to bind Bcl-XL, is localized to the cytosol, and promotes apoptosis.
Results

Rad9 undergoes proteolysis after DNA damage
To further characterize the role of Rad9 in apoptosis, the stability and modification of Rad9 were examined after treatment with genotoxic stress. Consistent with previous results (Volkmer and Karnitz, 1999; Komatsu et al., 2000b; St Onge et al., 2001) , when resolved on SDS-polyacrylamide gel (SDS-PAGE), Rad9 migrates as several distinct species ranging from 42 to 60 kDa even in the absence of genotoxic stress. These different bands are likely the result of phosphorylation, and can be seen in both treated and untreated cells (St. Onge et al., 1999 Volkmer and Karnitz, 1999; Komatsu et al., 2000b; Chen et al., 2001) . As shown in Figure 1 , for example, Rad9 appeared as three major species, designated Rad9a, Rad9b, and Rad9g, on Western blots. Interestingly, after treating U937 cells with incrementally increasing doses of ionizing radiation (IR), we observed that the lesser modified forms (b, g) of Rad9 decreased in a dose-dependent manner (Figure 1 ). This decrease does not directly translate into the increases in the highly modified form (Rad9a), suggesting that Rad9, especially the lesser modified forms (Rad9b and Rad9g), might undergo proteolysis after DNA damage. Reprobing the same blot with anticaspase-3 antibody revealed that the decrease in Rad9 protein level was concomitant to the activation of caspase-3 ( Figure 1 ). Upon analysis of the Rad9 protein sequence, we noticed that human Rad9 contains several potential caspase-3 cleavage sites ( Figure 2a ). For example, the sequence DDID (amino acids 301-304) is quite similar to the consensus motif DXXD for caspase-3 cleavage (Thornberry et al., 1997) .
Caspase-3 but not caspase-6 cleaves Rad9 in vitro
To determine whether caspase-3 can specifically cleave Rad9 in vitro,
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[S]methionine-labeled in vitro transcribed/translated (IVT) Rad9 was incubated with either purified active caspase-3 or caspase-6 (Stennicke and Salvesen, 1997). After incubation for 1 h at 371C, the resultant cleavage products were resolved on SDS-PAGE (15% gel) and exposed to X-ray film. As shown in Figure 2b , there were multiple species produced when incubated with caspase-3, whereas incubation with Figure 1 Human Rad9 is degraded after treatment with high-dose IR. U937 cells were treated with various doses of IR and cultured for 5 h after treatment. Lysate was prepared and subjected to SDS-PAGE, and transferred to nitrocellulose filters for analysis of Rad9 expression using a polyclonal anti-Rad9 antibody (top). The same blot was then stripped and reprobed with anti-caspase-3 antibody (bottom)
Caspase-3 cleavage of Rad9 MW Lee et al caspase-6 produced no cleavage fragment. The fact that there are multiple cleavage fragments generated after incubation with caspase-3 did not come as a surprise for, as indicated from the sequence analysis, there are several potential caspase cleavage sites in the Rad9 protein. To further assess caspase-3 cleavage of Rad9, we generated two point mutants: Rad9D304A, a single-point mutant in which the critical aspartic acid residue of DDID (AA: 301-304) was changed to alanine, and Rad9 DDD/ AAA, a triple-point mutant in which three aspartic acid residues of EEAD (AA: 184-187), SDTD (AA: 266-269), and DDID (AA: 301-304) were changed to alanines. The 35 S-labeled IVT Rad9 proteins were incubated with or without caspase-3, and the resulting fragments were resolved on a 15% SDS-PAGE gel and detected by autoradiography. Despite these mutations, some cleavage can still be seen (Figure 2c and d) , suggesting either the presence of minor cleavage sites or nonspecific proteolysis in vitro.
Rad9 is cleaved by caspase-3 in vivo
To determine whether Rad9 is cleaved in intact cells, we examined the processing of endogenous Rad9 in the human myeloid leukemia cell line U937 after treatment with IR. U937 cells were treated with high-dose IR (50 Gy), and analysed by Western blot for both cleavage of Rad9 and activation of caspase-3. Consistent with the results seen in Figure 1 , the less-modified forms of Rad9 (Rad9b and Rad9g) disappeared over time, and this coincided with the appearance of several faster migrating cleaved fragments (Figure 3a) . These cleavage fragments most likely represent C-terminal fragments, due to the fact that our Rad9 antibody recognizes the Cterminal portion of the protein. Also, there was a subtle modulation in the most highly phosphorylated form (Rad9a), although this species seems more resistant to IR-induced cleavage. The same blot was then stripped and reprobed with anti-caspase-3 antibody to show activation of caspase-3 concomitant to the appearance of the cleaved fragments of Rad9. To confirm that caspase-3 is the caspase responsible for Rad9 cleavage, U937 cells were exposed to 50 Gy IR in the presence or absence of either a pan-caspase inhibitor (z-VAD-fmk) or a caspase-3-specific inhibitor (z-DEVD-fmk). As seen in Figure 3b , incubation of cells with z-VAD-fmk but not the DMSO control abolished the proteolysis of Rad9 induced by IR treatment. Similar results were obtained when using the caspase-3-specific inhibitor z-DEVD-fmk (Figure 3c) . Moreover, STS, a protein Caspase-3 cleavage of Rad9 MW Lee et al kinase C inhibitor that activates caspase-3 and induces apoptosis, also caused the cleavage of Rad9 in U937 cells (Figure 4a ) but not the caspase-3-deficient cell line MCF-7 (Figure 4b ). These results, taken together, indicate that Rad9 is specifically cleaved by caspase-3 in cells.
Blockade of Rad9 cleavage decreases cell death in response to DNA-damaging agents
To ascertain the functional significance of Rad9 cleavage, we utilized the triple-point mutant Rad9 DDD/AAA, which shows dramatic resistance to caspase-3-mediated cleavage in vitro (Figure 2d) . We tested the efficacy of this mutant in HeLa cells cotransfected with either Myc-tagged wild-type or triple-mutant Rad9 DDD/AAA, together with Flag-Rad1 and HA-Hus1, and treated with 1.5 mm Doxorubicin for 20 h. As can be clearly seen in Figure 5a , the wild-type Rad9 protein is cleaved quite well, whereas the Rad9 DDD/AAA mutant remains intact and unchanged as compared to vehicle-treated cells. It is also important to note that conversion of these three aspartic residues in Rad9 to alanines does not alter its ability to form a complex with Rad1 and Hus1 (Figure 5b ). Consistent with these results, overexpression of Rad9 DDD/AAA mutant revealed a significant protective effect from DNA damage, as compared to wild-type Rad9 or control vector-transfected cells (Figure 5c ).
Cleavage coincides with cytosolic redistribution of Rad9
Previous findings have indicated that Rad9 can translocate to the cytosol after treatment with DNA-damaging agents, and that this translocation results in colocalization of Rad9 with Bcl-2 (Komatsu et al., 2000b; Hayashi et al., 2002) . Since cleavage of Rad9 by caspase-3 generates N-terminal fragments that harbor the BH3 domain, we reasoned that cleavage might contribute to the cytosolic translocation of Rad9. To test this hypothesis, we first treated the human breast cancer MDA-MB-468 cells with STS, and assayed for Rad9 cleavage and caspase-3 activation. As shown in (b) 293T cells were cotransfected with the same combinations of plasmid DNA as indicated in (a) for 24 h, and subjected to coimmunoprecipitation with anti-Myc affinity beads (Sigma). In addition to immune complexes, the whole-cell lysates (WCL) were applied directly to SDS-PAGE/immunoblot analysis. The blot was sequentially probed, striped, and reprobed with antibodies specific for c-Myc, Flag, and HA. *Denotes the residual signals from the previous immunoblotting. (c) HeLa cells were transfected as indicated above, and treated with 12.5 mg/ml etoposide for the indicated times before trypan blue staining
Caspase-3 cleavage of Rad9 MW Lee et al Figure 6a , a definite decrease in Rad9 protein level occurred in MDA-MB-468 cells after 3 h of STS treatment, which was concomitant to caspase-3 activation, although the cleavage fragments themselves were not as clearly visible as in U937 cells. Since we do not have antibodies available for detection of the N-terminal fragments of Rad9, we transfected MDA-MB-468 cells with GFP-tagged Rad9 to study the intracellular redistribution of Rad9 after STS treatment. Immunofluorescence analysis revealed that GFP-Rad9 was largely localized in the nucleus of untreated cells, but became a diffuse distribution throughout the cell after 2 h of STS treatment (Figure 6b ). It is important to note that, after 2 h of STS treatment, the nuclear membrane was still intact, although chromatin was beginning to condense or fragment. In contrast to wild-type Rad9 (w/t), the caspase-3-resistant Rad9 mutant (DDD/ AAA) remained in the nucleus after STS treatment (Figure 6b ).
The N-terminus of Rad9 interacts with Bcl-XL and induces apoptosis
To further investigate the intracellular localization of the N-terminal fragment of Rad9, we generated a Cterminal truncated mutant of Rad9 that mimics an Nterminal fragment of the cleaved Rad9 protein, and is expressed as a GFP fusion protein in HeLa cells. Consistent with the previous report (Hirai and Wang, 2002) , immunofluorescence microscopic analysis showed that GFP-Rad9DC was apparently distributed in the cytosol compared to the nuclear localization of GFPRad9 (Figure 7a ). Cells transfected with the GFP control protein revealed a mostly diffuse pattern of fluorescence ( Figure 7a ). Coimmunoprecipitation experiments indicated that the N-terminal fragment of Rad9 (Rad9DC) in which the BH3 domain resides was sufficient to associate with Bcl-XL (Figure 7b ), consistent with our previous results (Komatsu et al., 2000b) . Moreover, expression of Rad9DC mutant in 293 cells induced more apoptosis compared to those of cells transfected with wild-type Rad9 (Figure 7c ).
Discussion
Studies on substrate specificity, prodomain structure, and biological function have revealed that caspases are activated during apoptosis in a self-amplifying cascade (Salvesen and Dixit, 1997; Zimmermann et al., 2001) . Activation of the upstream caspases such as caspase-2, -8, -9, and -10 by proapoptotic signals leads to proteolytic activation of the downstream effector caspase-3, -6, and -7. The most prevalent caspase in the cell is caspase-3, and it is the one ultimately responsible for the majority of the apoptotic effects (Zimmermann et al., 2001) . Up to this point, several key proteins involved in DNA damage checkpoints or repair have been identified as targets of caspase-3. These proteins include poly-(ADP-ribose) polymerase (PARP), the DNA damage kinase ATM, the DNA repair recombinase Rad51, and the catalytic subunit of the DNA-dependent protein kinase (DNA-PKcs) (Nicholson, 1999) . Our findings indicate that Rad9, a human protein involved in the regulation of a cell-cycle checkpoint, is a substrate of caspase-3.
Previous work has provided data that support a role for Rad9, in a complex along with Rad family members Hus1 and Rad1, as a DNA damage sensor in the DNA Figure 6 Rad9 is cleaved in MDA-MB-468 cells, and translocates from the nucleus to the cytosol after induction of apoptosis. (a) MDA-MB-468 cells were treated with 1 mm STS for the designated times, and analysed by SDS-PAGE/immunoblot for Rad9 and caspase-3. b-Tubulin was used as a loading control. (b) MDA-MB-468 cells growing on glass cover slips were transfected with GFPRad9 (w/t) or GFP-Rad9 (DDD/AAA) for 24 h, and followed by treatment with 1 mm STS for the allotted times. Cells were then fixed with 3.7% formaldehyde for 30 min, and mounted onto microscope slides with mounting media containing the nuclear dye DAPI, and analysed via fluorescent microscopy integrity checkpoint (Zhou and Elledge, 2000; Caspari and Carr, 2002) . This putative complex, as revealed by molecular modeling analysis, bears sequence homology with the DNA-sliding clamp proliferating cell nuclear antigen (PCNA). (Aravind et al., 1999; Venclovas and Thelen, 2000) . The Rad9-Rad1-Hus1 complex is localized to the nucleus by the Rad9 nuclear localization sequence (NLS), where it then presumably initiates downstream signaling events for cell-cycle arrest in response to DNA damage (Hirai and Wang, 2002) . Another role outlined for Rad9 is as an arbiter of apoptosis via a conserved BH3 domain in the Nterminus of the Rad9 protein (Komatsu et al., 2000b; Yoshida et al., 2002) . Thus, the discovery that Rad9 is cleaved by caspase-3 adds a new, potentially interesting aspect to Rad9's involvement in apoptosis. We demonstrate that Rad9 is cleaved very efficiently by caspase-3 but not caspase-6. In response to DNA-damaging agents or STS treatment, Rad9 undergoes proteolysis in intact cells to generate several small fragments. The cleavage of Rad9 in vivo coincides with cleavage and activation of caspase-3, which can be inhibited by both a pan-caspase inhibitor and a caspase-3-specific inhibitor. Moreover, by mutating the major caspase-3 cleavage sites in Rad9, we generated a cleavage-resistant mutant that, when overexpressed, helps protect cells from death induced by DNA damage, while still retaining the ability to form the Rad9-Rad1-Hus1 checkpoint complex. Unfortunately, because the presently available antibodies for Rad9 are all C-terminus-directed, we could not visualize the cleaved N-terminal fragments of endogenous Rad9 by immunoblot analysis. However, a Rad9 mutant that corresponds to a potential cleavage product can serve as a proxy fragment to allow functional analysis of caspase-3-mediated cleavage of Rad9. This C-terminal deletion mutant of Rad9 nevertheless retains the ability to bind Bcl-XL in the cytosol, and to promote apoptosis. This then poses a potential dual role for cleavage that places Rad9 at the crux of a delicate balance between cell survival and programmed cell death. Burtelow et al. (2001) showed that the N-terminus of Rad9 interacts with the C-terminus of Rad1, the Nterminus of Rad1 interacts with the C-terminus of Hus1, and the N-terminus of Hus1 interacts with the Cterminus of Rad9, thus forming a 'doughnut'-like heterotrimeric complex. Therefore, the action of caspase-3 on Rad9 could be to serve as an indirect method of halting DNA repair in times of unrepairable damage via disruption of the Rad9-Rad1-Hus1 complex. Indeed, many polypeptides involved in DNA replication or repair such as PARP, DNA-PKcs, RAD51, p21 waf1/cip1 , as well as the large subunit of RFC, are cleaved in apoptotic cells (Earnshaw et al., 1999; Nicholson, 1999) . Thus, truncation of Rad9 would signal an abandonment of the 'sensor' role, as well as a loss of G2/M checkpoint integrity.
Cleavage may also serve as a cue for translocation and activation of Rad9 as an apoptosis-promoting protein through interaction with Bcl-2/Bcl-XL. Indeed, both full-length Rad9 and Rad9DC mutant are capable of binding to Bcl-XL, making a case for Rad9's antagonism of the antiapoptotic Bcl-2 family proteins. In times of DNA damage, a distinct pool of full-length Rad9 may function to inhibit Bcl-XL, while a separate pool continues to associate with Rad1 and Hus1, and engages in checkpoint control. Then, through an unknown mechanism, when it is determined that damage is too severe to survive or if it is energetically unfavorable to continue repair, Rad9 undergoes proteolysis, disrupting the Rad9 checkpoint complex. The resulting N-terminal fragments with the conserved BH3 domain of Rad9 then translocate to the cytosol, and interact with Bcl-2 or Bcl-XL, promoting apoptosis. 
Materials and methods
Expression plasmids
The pcDNA3-HA-Rad9, pCMV2-FLAG-Rad9, and pEGFP-C2-Rad9 have been previously described (Komatsu et al., 2000b) . The single-point mutant Rad9 (D304A) was created using a two-step polymerase chain reaction (PCR) method with pcDNA3-HA-Rad9 as a template. The triple-point mutation Rad9 (DDD/AAA) was generated with the Stratagene quick-change mutagenesis kit (Stratagene, CA, USA), using pcDNA3-HA-Rad9 as a template. The construction of pFLAG-Rad9DC, pcDNA-Myc-Rad9DC, and pEGFPRad9DC was accomplished by subcloning the PCR-amplified DNA fragment, encoding 1-267 amino acids of the human Rad9 protein into pFLAG-CMV2, pcDNA3-Myc or pEGFP-C2 (Clontech) vector.
Cell culture U937 cells were maintained in RPMI-1640 medium supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin G, and 100 mg/ml streptomycin. MDA-MB-468, 293, HeLa, and MCF-7 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FCS, 100 U/ml penicillin G, and 100 mg/ml streptomycin.
In vitro cleavage assays [ 35 S]methionine-labeled Rad9 proteins were generated using TNT-reticulocyte lysate kit (Promega), according to the manufacturer's recommendations.
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S-labeled proteins (5 ml) were placed into 10 ml of caspase reaction buffer (50 mm HEPES, pH 7.2, 100 mm NaCl, 1 mm EDTA, 0.1% Chaps, 5 mm DTT, 10% sucrose) containing either 0.75 ml of 20 mm active caspase-3 or 1.5 ml of 10 mm active caspase-6 (Stennicke and , and incubated at 371C for 30 min. Proteins were then resolved on SDS-PAGE (15%) and detected by autoradiography.
Immunoprecipitation/immunoblot assays
Cell lysates were prepared in NP-40 lysis buffer containing protease and phosphatase inhibitors (Komatsu et al., 2000b) , and normalized for protein content by BCA assay (Pierce). Immunoprecipitations were performed by incubating 500 mg of cell lysate with 20 ml of protein G-agarose preadsorbed with anti-FLAG M2 monoclonal antibody (Sigma) for 3 h at 41C. After multiple washes in lysis buffer, the beads were resuspended in 25 ml of Laemmli buffer, boiled, and subjected to immunoblotting analysis using polyclonal antibodies specific for FLAG (Sigma) or Bcl-XL (PharMingen).
Apoptosis assay
293 cells were transfected with pEGFP-C2, pEGFP-Rad9, or pEGFP-Rad9DC plasmid DNA for 24 h. Cells were fixed with 3.7% formaldehyde, stained with 4 0 ,6-diamino-2-phenylinoodole (DAPI), and visualized by fluorescent microscopy. Cells with clear condensed chromatin and/or fragmented nuclei were determined as apoptosis.
